ELEV - Elevation Oncology, Inc. Stock Price and Quote

ELEV [NASD]

Index	-	P/E	-	EPS (ttm)	-4.06	Insider Own	0.10%	Shs Outstand	23.29M	Perf Week	9.00%
Market Cap	25.20M	Forward P/E	-	EPS next Y	-2.31	Insider Trans	0.00%	Shs Float	22.79M	Perf Month	45.33%
Income	-85.70M	PEG	-	EPS next Q	-0.78	Inst Own	73.00%	Short Float / Ratio	0.15% / 0.43	Perf Quarter	14.54%
Sales	-	P/S	-	EPS this Y	-248.60%	Inst Trans	-5.93%	Short Interest	0.03M	Perf Half Y	-14.84%
Book/sh	2.88	P/B	0.37	EPS next Y	42.40%	ROA	-66.00%	Target Price	4.17	Perf Year	-71.87%
Cash/sh	4.54	P/C	0.23	EPS next 5Y	-	ROE	-78.50%	52W Range	0.72 - 5.20	Perf YTD	14.74%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-79.04%	Beta	-
Dividend %	-	Quick Ratio	7.30	Sales past 5Y	-	Gross Margin	-	52W Low	50.78%	ATR	0.09
Employees	48	Current Ratio	7.30	Sales Q/Q	-	Oper. Margin	-	RSI (14)	55.51	Volatility	6.33% 11.24%
Optionable	No	Debt/Eq	0.44	EPS Q/Q	-215.70%	Profit Margin	-	Rel Volume	3.23	Prev Close	1.06
Shortable	Yes	LT Debt/Eq	0.44	Earnings	-	Payout	-	Avg Volume	78.96K	Price	1.09
Recom	2.40	SMA20	6.27%	SMA50	10.41%	SMA200	-25.08%	Volume	98,964	Change	2.83%

Dec-23-21

Initiated

H.C. Wainwright

Buy

$12

Jan-09-23 07:30AM	Elevation Oncology to Present at the 41st Annual J.P. Morgan Healthcare Conference PR Newswire +6.29%
Jan-06-23 08:15AM	Elevation Oncology Announces Pipeline Prioritization, Realignment of Resources to Advance EO-3021 and CEO Transition PR Newswire -28.57%
Nov-30-22 07:30AM	Elevation Oncology to Participate at the JMP Securities Hematology and Oncology Summit PR Newswire
Nov-03-22 07:30AM	Elevation Oncology Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress PR Newswire -6.47%
Aug-12-22 09:30AM	10 Best One Dollar Stocks To Buy Now Insider Monkey
07:30AM	Loading…
Aug-04-22 07:30AM	Elevation Oncology Reports Second Quarter 2022 Financial Results and Highlights Recent Company Progress PR Newswire +9.48%
Aug-03-22 08:00AM	Elevation Oncology to Participate at the Wedbush PacGrow Healthcare Conference PR Newswire
Jul-28-22 08:50AM	Elevation Oncology Secures $50 Million Loan Facility with K2 HealthVentures PR Newswire -12.77%
08:45AM	Elevation Oncology Expands Pipeline through Exclusive Licensing of EO-3021 (SYSA1801), a Clinical Stage Anti-Claudin18.2 Antibody Drug Conjugate, From CSPC Pharmaceutical Group PR Newswire
Jul-14-22 08:45AM	10 Best Penny Stocks to Buy in July Insider Monkey
Jun-01-22 07:30AM	Elevation Oncology to Participate at Cowen's 3rd Annual Oncology Innovation Summit PR Newswire
May-26-22 05:05PM	Elevation Oncology to Present Initial Seribantumab Proof-of-Concept Data from Phase 2 CRESTONE Study in Patients with Tumors Harboring NRG1 Fusions at ASCO 2022 PR Newswire -14.97%
08:27AM	Estimating The Intrinsic Value Of Elevation Oncology, Inc. (NASDAQ:ELEV) Simply Wall St.
May-25-22 07:30AM	Elevation Oncology Announces FDA Fast Track Designation Granted to Seribantumab for the Tumor-Agnostic Treatment of Solid Tumors Harboring NRG1 Gene Fusions PR Newswire +11.93%
May-05-22 07:30AM	Elevation Oncology Reports First Quarter 2022 Financial Results and Highlights Recent Company Progress PR Newswire +19.67%
10:05AM	Loading…
Apr-27-22 10:05AM	Elevation Oncology Announces Initial Data from Phase 2 CRESTONE Study of Seribantumab Selected for Oral Presentation at ASCO 2022 PR Newswire +16.39%
Mar-24-22 01:12PM	Is Elevation Oncology (NASDAQ:ELEV) In A Good Position To Deliver On Growth Plans? Simply Wall St. +5.95%
Mar-14-22 07:00AM	Elevation Oncology Appoints David Dornan, Ph.D., as Chief Scientific Officer PR Newswire -6.36%
Mar-03-22 07:30AM	Elevation Oncology Reports Fourth Quarter and Full Year 2021 Financial Results PR Newswire
Mar-01-22 07:00AM	Elevation Oncology to Participate at Upcoming Virtual Investor Conferences PR Newswire
Jan-10-22 07:00AM	Elevation Oncology Highlights 2021 Achievements and Outlines Expected 2022 Milestones PR Newswire
Jan-06-22 08:00AM	Elevation Oncology to Present at the H.C. Wainwright BIOCONNECT Virtual Conference PR Newswire
Jan-05-22 08:00AM	Elevation Oncology to Present at the 40th Annual J.P. Morgan Healthcare Conference PR Newswire
Dec-16-21 09:14AM	10 Micro-Cap Stocks to Buy According to Hedge Funds Insider Monkey
Nov-18-21 08:00AM	Elevation Oncology to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference PR Newswire
Nov-12-21 07:30AM	Elevation Oncology Reports Third Quarter 2021 Financial Results PR Newswire -7.01%
Oct-20-21 07:00AM	Elevation Oncology Announces the Promotion of Valerie Malyvanh Jansen, M.D., Ph.D., to Chief Medical Officer PR Newswire
Oct-14-21 07:00AM	Elevation Oncology's Seribantumab Included as Part of a Case Series Presentation at the Australasian Gastro-Intestinal Trials Group 2021 Annual Scientific Meeting PR Newswire -5.13%
Sep-25-21 09:52AM	Elevation Oncology (NASDAQ:ELEV) Is In A Good Position To Deliver On Growth Plans Simply Wall St.
Sep-07-21 07:00AM	Elevation Oncology to Present at the H.C. Wainwright 23rd Annual Global Investment Conference PR Newswire
04:05PM	Loading…
Aug-12-21 04:05PM	Elevation Oncology Reports Second Quarter 2021 Financial Results PR Newswire
Aug-04-21 07:00AM	Elevation Oncology to Present at the 12th Annual Wedbush PacGrow Healthcare Conference PR Newswire
Jun-24-21 08:44PM	Elevation Oncology Announces Pricing of Initial Public Offering PR Newswire

Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company's lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced solid tumors harboring a neuregulin-1 fusion. Elevation Oncology, Inc. was incorporated in 2019 and is based in New York, New York.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
venBio Global Strategic Fund I	10% Owner	May 25	Sale	4.12	702,737	2,897,806	1,905,430	May 27 07:20 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Upgrade your FINVIZ experience